Business Context and Reporting Period
This Form 8-K Current Report was filed by Senseonics Holdings, Inc. on January 12, 2021, covering events occurring on December 23, 2020, and January 11, 2021. The filing primarily addresses a Regulation FD disclosure regarding financial and operational updates and the final closing of a private placement financing.
Key Financial Metrics and Capital Events
- Financing Completion: On January 11, 2021, the Company completed the final closing of a private placement of Series A Preferred Stock.
- Total Proceeds: The Company sold a total of $25.8 million of Series A Preferred Stock to Masters Special Situations, LLC, Marlin Fund, Limited Partnership, Marlin Fund II, Limited Partnership, and certain assignees.
- Board Representation: Masters Special Situations, LLC retained the right to designate one director for election to the Company's board of directors at the 2021 Annual Meeting.
- Registration Rights: The deadline for filing a resale registration statement for shares of common stock issuable upon conversion of the Series A Preferred Stock was extended to February 15, 2021.
- Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels for the reporting period.
Material Changes and Operational Updates
- FDA Regulatory Delay: The Company received notification from the U.S. Food and Drug Administration (FDA) that resource reallocation to address COVID-19 Emergency Use Authorization (EUA) applications is delaying marketing application reviews. The review for the Eversense 180-day product is expected to be delayed by at least 60 days.
- Revised Approval Timeline: Despite the delay, the Company believes there is potential for an FDA decision by the end of the second quarter of 2021.
- Reimbursement Update: The Centers for Medicare & Medicaid Services (CMS) included Eversense Category III CPT codes in the 2021 Physician Fee Schedule, establishing global payment for device costs and procedure fees for U.S. healthcare providers.
- Distribution Transition: The Company entered an agreement with Roche to transition distribution activities in European territories to Ascensia Diabetes Care, effective February 1, 2021. This includes winding up Roche's distribution activities and resolving final purchase matters.
Outlook, Risks, and Contingencies
- Forward-Looking Statements: The Company issued a disclaimer regarding future expectations, including FDA approval of the 180-day Eversense product and the European distribution transition.
- Key Risks:
- Uncertainty regarding the duration and severity of FDA resource reallocation due to the COVID-19 pandemic.
- Volume of EUA requests impacting FDA review timelines.
- Uncertainties associated with transitioning European distribution from Roche to Ascensia.
- Management Commentary: Management noted that multiple sponsors have received similar notifications regarding FDA delays and emphasized that the precise duration of the delay cannot be known due to pandemic-related uncertainties.
Investor Verification Checklist
- Verify the exact timing of the FDA decision for the Eversense 180-day product against the projected end of Q2 2021 timeline.
- Confirm the successful commencement of distribution by Ascensia Diabetes Care in European territories on February 1, 2021.
- Monitor the filing of the resale registration statement by the February 15, 2021 deadline.
- Review the impact of the 60-day FDA delay on the Company's cash burn rate and liquidity position relative to the $25.8 million raised.
- Assess the adoption rate of the new CMS Category III CPT codes by healthcare providers in the U.S.